WO2005087706A1 - Processes for the preparation of stable polymorph of sertraline hydrochloride - Google Patents

Processes for the preparation of stable polymorph of sertraline hydrochloride Download PDF

Info

Publication number
WO2005087706A1
WO2005087706A1 PCT/IB2005/000612 IB2005000612W WO2005087706A1 WO 2005087706 A1 WO2005087706 A1 WO 2005087706A1 IB 2005000612 W IB2005000612 W IB 2005000612W WO 2005087706 A1 WO2005087706 A1 WO 2005087706A1
Authority
WO
WIPO (PCT)
Prior art keywords
sertraline hydrochloride
solvent
stable form
preparation
sertraline
Prior art date
Application number
PCT/IB2005/000612
Other languages
French (fr)
Inventor
Yatendra Kumar
Mohan Prasad
Kaptan Singh
Kintali Venkata Ramana
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2005087706A1 publication Critical patent/WO2005087706A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Definitions

  • the field of the invention relates to processes for the preparation of a polymorph of sertraline hydrochloride. More particularly, it relates to the preparation of a stable polymorph of sertraline hydrochloride and pharmaceutical compositions that include the stable polymorph of sertraline hydrochloride. The invention also relates to use of the compositions for treating anxiety related disorders. Background of the Invention Chemically, sertraline hydrochloride is (lS-cis)-4-(3,4-dichlorophenyl)-l,2,3,4- tetrahydro-N-methyl-1-naphthalenamine hydrochloride having the structural Formula I.
  • Sertraline hydrochloride is known to exhibit polymorphism and exists in several crystalline forms and amorphous fonn having different physical properties. These different solid-state physical forms may be obtained by controlling the conditions under which the sertraline hydrochloride is obtained in the solid form.
  • the solid-state form of a compound is also known to affect its behavior on compaction and its storage stability.
  • U.S.Patent No. 4,536,518 discloses a process for the preparation of sertraline hydrochloride having a melting point of 243-245°C by treating an ethyl acetate/ether solution of the free base with gaseous hydrogen chloride.
  • U.S.Patent No. 4,536,518 discloses a process for the preparation of sertraline hydrochloride having a melting point of 243-245°C by treating an ethyl acetate/ether solution of the free base with gaseous hydrogen chloride.
  • Patent No. 5,248,699 discloses processes for the preparation of five crystalline forms of sertraline hydrochloride, designated Fonn I, Form II, Form III, Form IV and Form V by rapid crystallization of sertraline hydrochloride from an organic solvent.
  • the patent also discloses that Forms II, III, IN and N are metastable, and that granulation of Forms II, III or IN in isopropyl alcohol, ethyl acetate, hexane at a temperature from about 40-60°C causes conversion to Form I.
  • WO 00/32551 and WO 03/51818 describe processes for the preparation of various polymorphic forms of sertraline hydrochloride and their conversion to each other.
  • These applications disclose the preparation of Form II by dissolving sertraline mandelate or free sertraline base in an organic solvent and treating with hydrogen chloride at ambient to reflux temperature.
  • U.S. Patent No. 6,495,721 discloses several processes for the preparation of Form
  • One of the processes disclosed for the preparation of Form II involves dissolving sertraline hydrochloride in an organic solvent such as acetone, cyclohexanol and dimethylformamide and heating the solution for sufficient time to effect the transformation to Form II of sertraline hydrochloride followed by isolation of Form II.
  • organic solvent such as acetone, cyclohexanol and dimethylformamide
  • WO 01/32601 discloses processes for the preparation of sertraline hydrochloride polymorphic form II from a solution of sertraline free amine with some seeding crystals of form II before the addition of a solution of hydrogen chloride; or from a stirred suspension of sertraline hydrochloride polymorphic form V with some seeding crystals of sertraline hydrochloride polymorphic form II; or by drying a sertraline hydrochloride alcohol solvate at temperatures firom about 0 to 30°C in high vacuum (less than I mbar); or from stirred suspensions of sertraline hydrochloride polymorphic form CSC1, CSC2 or TI with some seeding crystals of sertraline hydrochloride polymorphic Form II.
  • Sertraline hydrochloride polymorphic form II may be formed according to a process in which a solution of sertraline free amine is seeded with some crystals of polymorphic form II and a solution of hydrogen chloride is added.
  • WO 02/096859 discloses processes for the preparation of sertraline hydrochloride
  • WO 03/93217 discloses sertraline hydrochloride Form II which is substantially free of other polymorphic forms. The inventors have found that the prior art approach for the preparation of polymorph form II is not suitable from a commercial point of view because the sertraline hydrochloride so obtained has a tendency to undergo discoloration upon storage. The present invention provides a process which results in a storage stable polymorph fonn II of sertraline hydrochloride.
  • the polymorph form II of sertraline hydrochloride when made by the process of the present invention is easy to isolate and handle, thus making the process amenable for commercial scale use.
  • Summary of the Invention hi one general aspect there is provided a storage stable polymorph form II of sertraline hydrochloride.
  • the Form II of sertraline hydrochloride may have, for example, the X-ray powder diffraction pattern of Figure 1.
  • a pharmaceutical composition that includes a therapeutically effective amount of the storage stable polymorph form II of sertraline hydrochloride; and one or more pharmaceutically acceptable carriers, excipients or diluents.
  • a process for the preparation of stable polymo ⁇ h form II of sertraline hydrochloride hi another general aspect there is provided a process for the preparation of stable polymo ⁇ h form II of sertraline hydrochloride.
  • the process includes obtaining a suspension of sertraline hydrochloride in a solvent comprising one or more of methyl isobutyl ketone, N,N-dimethylacetamide or N,N-dimethylformamide; heating the suspension; and recovering the stable Form II of sertraline hydrochloride by the removal of the solvent.
  • Removing the solvent may include, for example, one or more of filtration, filtration under vacuum, decantation and centrifugation.
  • the process may include further forming of the product so obtained into a finished dosage form.
  • the process may include further drying of the product obtained. i one general aspect, the solution may be cooled before filtration to obtain better yields of the stable Form II of sertraline hydrochloride.
  • the solution may be seeded with crystals of Form II resulting in the precipitation of the Form II of sertraline hydrochloride and removing the solvent there from by filtration, filtration under vacuum, decantation or centrifugation.
  • the sertraline hydrochloride which is used as the starting material may be obtained by any of the known processes, for example, processes as disclosed in U.S. Patent No. 4,536,518; U.S. Patent No. 5,248,699; WO 00/32551; and WO 01/32601.
  • a process for the preparation of storage stable Form II of sertraline hydrochloride there is provided a process for the preparation of storage stable Form II of sertraline hydrochloride.
  • the process includes washing the Form II of sertraline hydrochloride with a dilute solution of an antioxidant in a solvent; and recovering the storage stable Form II of sertraline hydrochloride by the removal of the solvent.
  • the solvent may be, for example, one or more of methyl isobutyl ketone, N,N- dimethylacetamide, N,N-dimethylformamide, or mixtures thereof.
  • the antioxidant may be any conventional antioxidant used in the pharmaceutical industry, for example, butylated hydroxyanisole (BHLA), butylated hydroxytoluene (BHT), hydroquinone, propyl gallate, ascorbyl palmitate, octyl gallate, dodecyl gallate, tocopherols, sodium or calcium ascorbate, tert-butylated hydroquinone, and the like.
  • Removing the solvent may include, for example, one or more of filtration, filtration under vacuum, decantation and centrifugation.
  • the process may include further forming of the product so obtained into a finished dosage form.
  • the process may include further drying of the product obtained.
  • the washing may be carried out by making a slurry in the dilute solution of an antioxidant in a solvent.
  • wet solid Form II sertraline hydrochloride obtained from the process of its preparation may be washed before drying the product.
  • the form II sertraline hydrochloride may be dried before washing with a dilute solution of an antioxidant in a solvent.
  • the sertraline hydrochloride Form II may be obtained by any of the processes known in the art, for example, U.S. Patent No. 4,536,518.
  • the stable Form II sertraline hydrochloride prepared above may be used for the preparation of storage stable Form II sertraline hydrochloride.
  • the process may produce a storage stable Form II sertraline hydrochloride having the X-ray diffraction pattern of Figure 1, and which does not undergo discoloration during its shelf-life.
  • a method for treating the anxiety related disorders in a warm-blooded animal comprising providing the warm-blooded animal a pharmaceutical composition that includes the storage stable Form II sertraline hydrochloride.
  • the inventors have developed processes for the preparation of the stable Form II of sertraline hydrochloride.
  • the Form II sertraline hydrochloride is characterized by its X- ray diffraction pattern as shown in Figure 1.
  • the inventors have developed a process for the preparation of the stable Form II of sertraline hydrochloride by obtaining a suspension of sertraline hydrochloride in a solvent comprising one or more of methyl isobutyl ketone, N,N-dimethylacetamide or N,N-dimethylformamide; heating the suspension; and recovering the stable Form II of sertraline hydrochloride by the removal of the solvent.
  • the inventors have also developed pharmaceutical compositions that contain the stable Form II of sertraline hydrochloride in admixture with one or more solid or liquid pharmaceutical diluents, carriers, and/or excipients.
  • the suspension of sertraline hydrochloride may be obtained by suspending sertraline hydrochloride in a suitable solvent. Alternatively, such a suspension may be obtained directly from a reaction in which sertraline hydrochloride is formed.
  • the suspension containing sertraline hydrochloride may be heated to obtain a solution. It may be heated from about 30°C to about 200°C, for example from about 50°C to about 150°C. It may be heated from about 10 minutes to about 24 hours. More particularly, it may be heated for about 2-3 hours.
  • the sertraline hydrochloride can be prepared by methods described in U.S. Patent
  • sertraline hydrochloride includes all polymorphic forms, amorphous form, solvates, hydrates, or mixtures thereof.
  • the solvent may be removed from the solution by a technique which includes, for example, filtration, filtration under vacuum, decantation and centrifugation. h one aspect the solution may be cooled before filtration to obtain better yields of the stable Form II of sertraline hydrochloride. It maybe cooled from about 100°C to about -50°C, for example from about 50°C to about -10°C.
  • the solution may be seeded with crystals of Form II resulting in the precipitation of the Form II of sertraline hydrochloride and removing the solvent there from by filtration, filtration under vacuum, decantation or centrifugation.
  • the product obtained may be further or additionally dried to achieve the desired moisture values.
  • the product may be further or additionally dried in a tray drier, dried under vacuum and/or in a Fluid Bed Dryer. The inventors have developed a process for the preparation of the storage stable
  • Form II of sertraline hydrochloride The process includes washing the Form II of sertraline hydrochloride with a dilute solution of an antioxidant in a solvent; and recovering the storage stable Form II of sertraline hydrochloride by the removal of the solvent.
  • the Form II of sertraline hydrochloride in dry solid state may be washed.
  • wet solid Form II of sertraline hydrochloride obtained from the process to prepare Form II sertraline hydrochloride may directly be washed without drying it.
  • the washing involves making a slurry of Form II sertraline hydrochloride in a dilute solution of an antioxidant in a suitable solvent.
  • solvent includes any solvent or solvent mixture in which Form II sertraline hydrochloride is insoluble or very slightly soluble or sparingly soluble, including, for example methyl isobutyl ketone, N,N-dimethylacetamide, N,N- dimethylformamide, or mixtures thereof.
  • the antioxidant may include conventional antioxidants used in the pharmaceutical industry, for example butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), hydroquinone, propyl gallate, ascorbyl palmitate, octyl gallate, dodecyl gallate, tocopherols, sodium or calcium ascorbate, tert-butylated hydroquinone, and the like.
  • the resulting storage stable Form II of sertraline hydrochloride does not get discolored during its entire shelf life. It may be formulated into ordinary dosage forms such as, for example, tablets, capsules, pills, solutions, etc. h these cases, the medicaments can be prepared by conventional methods with conventional pharmaceutical excipients.
  • the compositions include dosage forms suitable for oral, buccal, rectal, and parenteral (including subcutaneous, intramuscular, and ophthalmic) administration.
  • the oral dosage forms may include solid dosage forms, like powder, tablets, capsules, suppositories, sachets, troches and lozenges as well as liquid suspensions, emulsions, pastes and elixirs.
  • Parenteral dosage forms may include intravenous infusions, sterile solutions for intramuscular, subcutaneous or intravenous administration, dry powders to be reconstituted with sterile water for parenteral administration, and the like.
  • the storage stable Fonn II of sertraline hydrochloride can be administered for the treatment of anxiety-related disorders, symptoms associated with premenstrual disorders and late luteal phase dysphoric disorders, in a warm-blooded animal.
  • a warm-blooded animal is a member of the animal kingdom possessed of a homeostatic mechanism and includes mammals and birds.
  • the present invention is further illustrated by the following examples which are provided merely to be exemplary of the invention and do not limit the scope of the invention.
  • Example 1 Preparation of stable sertraline hydrochloride Form II
  • Sertraline hydrochloride (1.0 g) was suspended in methyl isobutyl ketone (20 ml) at room temperature and the reaction mixture was heated slowly to 80°C. The reaction mixture was stirred at 80°C for about 2 hours and then cooled to room temperature. The product was filtered and dried under vacuum. The XRD pattern as per Figure 1 showed it to be a Form II of sertraline hydrochloride.
  • Example 2 Preparation of stable sertraline hydrochloride Form II Sertraline hydrochloride (1.0 g) was dissolved in dimethylacetamide (20 ml) at room temperature and the reaction mixture was heated slowly to 80°C. The reaction mixture was stirred at 80°C for about 2 hours and then cooled to -5°C. The product was filtered and dried under vacuum.
  • the XRD pattern as per Figure 1 showed it to be a Form II of sertraline hydrochloride.
  • Example 3 Preparation of storage stable sertraline hydrochloride Form II
  • Sertraline hydrochloride 1.0 g was suspended in methyl isobutyl ketone (20 ml) at room temperature and the reaction mixture was heated slowly to 80°C. The reaction mixture was stirred at 80°C for about 2 hours and then cooled to room temperature. The product was filtered and washed with a solution of butylated hydroxyanisole (0.1 g in 2 ml methyl isobutyl ketone) and then dried under vacuum.
  • the XRD pattern as per Figure 1 showed it to be a Form II of sertraline hydrochloride.
  • a measure of discoloration can be obtained by measuring UV absorbance.
  • the UN absorbance of Example 3 (5% solution in methanol at about 380nm) was found to be 0.069 after storage for one year at 30°C and 55% humidity.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to a process for the preparation of a polymorph of sertraline hydrochloride. More particularly, it relates to the preparation of a stable polymorph of sertraline hydrochloride and pharmaceutical compositions that include the stable polymorph of sertraline hydrochloride. The invention also relates to use of said compositions for treating anxiety related disorders.

Description

PROCESSES FOR THE PREPARATION OF STABLE POLYMORPH OF SERTRALINE HYDROCHLORIDE Field of the Invention The field of the invention relates to processes for the preparation of a polymorph of sertraline hydrochloride. More particularly, it relates to the preparation of a stable polymorph of sertraline hydrochloride and pharmaceutical compositions that include the stable polymorph of sertraline hydrochloride. The invention also relates to use of the compositions for treating anxiety related disorders. Background of the Invention Chemically, sertraline hydrochloride is (lS-cis)-4-(3,4-dichlorophenyl)-l,2,3,4- tetrahydro-N-methyl-1-naphthalenamine hydrochloride having the structural Formula I. It is useful in the treatment of anxiety-related disorders (U.S. Patent No. 4,962,128), symptoms associated with premenstrual disorders (U.S. Patent No. 5,789,449) and late luteal phase dysphoric disorder (U.S. Patent No. 5,744,501).
Figure imgf000002_0001
FORMULA I Sertraline hydrochloride is known to exhibit polymorphism and exists in several crystalline forms and amorphous fonn having different physical properties. These different solid-state physical forms may be obtained by controlling the conditions under which the sertraline hydrochloride is obtained in the solid form. The solid-state form of a compound is also known to affect its behavior on compaction and its storage stability. Several processes have been reported for the preparation of various polymorphs of sertraline hydrochloride. U.S.Patent No. 4,536,518 discloses a process for the preparation of sertraline hydrochloride having a melting point of 243-245°C by treating an ethyl acetate/ether solution of the free base with gaseous hydrogen chloride. U.S. Patent No. 5,248,699 discloses processes for the preparation of five crystalline forms of sertraline hydrochloride, designated Fonn I, Form II, Form III, Form IV and Form V by rapid crystallization of sertraline hydrochloride from an organic solvent. The patent also discloses that Forms II, III, IN and N are metastable, and that granulation of Forms II, III or IN in isopropyl alcohol, ethyl acetate, hexane at a temperature from about 40-60°C causes conversion to Form I. WO 00/32551 and WO 03/51818 describe processes for the preparation of various polymorphic forms of sertraline hydrochloride and their conversion to each other. These applications disclose the preparation of Form II by dissolving sertraline mandelate or free sertraline base in an organic solvent and treating with hydrogen chloride at ambient to reflux temperature. U.S. Patent No. 6,495,721 discloses several processes for the preparation of Form
II of sertraline hydrochloride. One of the processes disclosed for the preparation of Form II involves dissolving sertraline hydrochloride in an organic solvent such as acetone, cyclohexanol and dimethylformamide and heating the solution for sufficient time to effect the transformation to Form II of sertraline hydrochloride followed by isolation of Form II. WO 01/32601 discloses processes for the preparation of sertraline hydrochloride polymorphic form II from a solution of sertraline free amine with some seeding crystals of form II before the addition of a solution of hydrogen chloride; or from a stirred suspension of sertraline hydrochloride polymorphic form V with some seeding crystals of sertraline hydrochloride polymorphic form II; or by drying a sertraline hydrochloride alcohol solvate at temperatures firom about 0 to 30°C in high vacuum (less than I mbar); or from stirred suspensions of sertraline hydrochloride polymorphic form CSC1, CSC2 or TI with some seeding crystals of sertraline hydrochloride polymorphic Form II. Furthermore, Sertraline hydrochloride polymorphic form II may be formed according to a process in which a solution of sertraline free amine is seeded with some crystals of polymorphic form II and a solution of hydrogen chloride is added. WO 02/096859 discloses processes for the preparation of sertraline hydrochloride
Form II by extracting or dissolving the sertraline base into ethyl acetate, adding isopropanol as a solvent, adding hydrogen chloride dissolved in ethyl acetate or in gaseous form, and isolating the sertraline hydrochloride polymorphic Form II. WO 03/93217 discloses sertraline hydrochloride Form II which is substantially free of other polymorphic forms. The inventors have found that the prior art approach for the preparation of polymorph form II is not suitable from a commercial point of view because the sertraline hydrochloride so obtained has a tendency to undergo discoloration upon storage. The present invention provides a process which results in a storage stable polymorph fonn II of sertraline hydrochloride. The polymorph form II of sertraline hydrochloride when made by the process of the present invention is easy to isolate and handle, thus making the process amenable for commercial scale use. Summary of the Invention hi one general aspect there is provided a storage stable polymorph form II of sertraline hydrochloride. The Form II of sertraline hydrochloride may have, for example, the X-ray powder diffraction pattern of Figure 1. h another general aspect there is provided a pharmaceutical composition that includes a therapeutically effective amount of the storage stable polymorph form II of sertraline hydrochloride; and one or more pharmaceutically acceptable carriers, excipients or diluents. hi another general aspect there is provided a process for the preparation of stable polymoφh form II of sertraline hydrochloride. The process includes obtaining a suspension of sertraline hydrochloride in a solvent comprising one or more of methyl isobutyl ketone, N,N-dimethylacetamide or N,N-dimethylformamide; heating the suspension; and recovering the stable Form II of sertraline hydrochloride by the removal of the solvent. Removing the solvent may include, for example, one or more of filtration, filtration under vacuum, decantation and centrifugation. The process may include further forming of the product so obtained into a finished dosage form. The process may include further drying of the product obtained. i one general aspect, the solution may be cooled before filtration to obtain better yields of the stable Form II of sertraline hydrochloride. In another general aspect, the solution may be seeded with crystals of Form II resulting in the precipitation of the Form II of sertraline hydrochloride and removing the solvent there from by filtration, filtration under vacuum, decantation or centrifugation. The sertraline hydrochloride which is used as the starting material may be obtained by any of the known processes, for example, processes as disclosed in U.S. Patent No. 4,536,518; U.S. Patent No. 5,248,699; WO 00/32551; and WO 01/32601. In another general aspect there is provided a process for the preparation of storage stable Form II of sertraline hydrochloride. The process includes washing the Form II of sertraline hydrochloride with a dilute solution of an antioxidant in a solvent; and recovering the storage stable Form II of sertraline hydrochloride by the removal of the solvent. The solvent may be, for example, one or more of methyl isobutyl ketone, N,N- dimethylacetamide, N,N-dimethylformamide, or mixtures thereof. The antioxidant may be any conventional antioxidant used in the pharmaceutical industry, for example, butylated hydroxyanisole (BHLA), butylated hydroxytoluene (BHT), hydroquinone, propyl gallate, ascorbyl palmitate, octyl gallate, dodecyl gallate, tocopherols, sodium or calcium ascorbate, tert-butylated hydroquinone, and the like. Removing the solvent may include, for example, one or more of filtration, filtration under vacuum, decantation and centrifugation. The process may include further forming of the product so obtained into a finished dosage form. The process may include further drying of the product obtained. hi one general aspect, the washing may be carried out by making a slurry in the dilute solution of an antioxidant in a solvent. In one general aspect, wet solid Form II sertraline hydrochloride obtained from the process of its preparation may be washed before drying the product. i another general aspect, the form II sertraline hydrochloride may be dried before washing with a dilute solution of an antioxidant in a solvent. The sertraline hydrochloride Form II may be obtained by any of the processes known in the art, for example, U.S. Patent No. 4,536,518. The stable Form II sertraline hydrochloride prepared above may be used for the preparation of storage stable Form II sertraline hydrochloride. The process may produce a storage stable Form II sertraline hydrochloride having the X-ray diffraction pattern of Figure 1, and which does not undergo discoloration during its shelf-life. In another general aspect there is provided a method for treating the anxiety related disorders in a warm-blooded animal, the method comprising providing the warm-blooded animal a pharmaceutical composition that includes the storage stable Form II sertraline hydrochloride. The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects and advantages of the inventions will be apparent from the description and claims. Description of the Drawings Figure 1 is an X-ray powder diffraction pattern of stable Form II of sertraline hydrochloride. Detailed Description of the Invention The inventors have developed processes for the preparation of the stable Form II of sertraline hydrochloride. The Form II sertraline hydrochloride is characterized by its X- ray diffraction pattern as shown in Figure 1. The inventors have developed a process for the preparation of the stable Form II of sertraline hydrochloride by obtaining a suspension of sertraline hydrochloride in a solvent comprising one or more of methyl isobutyl ketone, N,N-dimethylacetamide or N,N-dimethylformamide; heating the suspension; and recovering the stable Form II of sertraline hydrochloride by the removal of the solvent. The inventors have also developed pharmaceutical compositions that contain the stable Form II of sertraline hydrochloride in admixture with one or more solid or liquid pharmaceutical diluents, carriers, and/or excipients. hi general, the suspension of sertraline hydrochloride may be obtained by suspending sertraline hydrochloride in a suitable solvent. Alternatively, such a suspension may be obtained directly from a reaction in which sertraline hydrochloride is formed. The suspension containing sertraline hydrochloride may be heated to obtain a solution. It may be heated from about 30°C to about 200°C, for example from about 50°C to about 150°C. It may be heated from about 10 minutes to about 24 hours. More particularly, it may be heated for about 2-3 hours. The sertraline hydrochloride can be prepared by methods described in U.S. Patent
No. 4,536,518; U.S. Patent No. 5,248,699; WO 00/32551; and WO 01/32601. The term "sertraline hydrochloride" includes all polymorphic forms, amorphous form, solvates, hydrates, or mixtures thereof. The solvent may be removed from the solution by a technique which includes, for example, filtration, filtration under vacuum, decantation and centrifugation. h one aspect the solution may be cooled before filtration to obtain better yields of the stable Form II of sertraline hydrochloride. It maybe cooled from about 100°C to about -50°C, for example from about 50°C to about -10°C. In another aspect, the solution may be seeded with crystals of Form II resulting in the precipitation of the Form II of sertraline hydrochloride and removing the solvent there from by filtration, filtration under vacuum, decantation or centrifugation. The product obtained may be further or additionally dried to achieve the desired moisture values. For example, the product may be further or additionally dried in a tray drier, dried under vacuum and/or in a Fluid Bed Dryer. The inventors have developed a process for the preparation of the storage stable
Form II of sertraline hydrochloride. The process includes washing the Form II of sertraline hydrochloride with a dilute solution of an antioxidant in a solvent; and recovering the storage stable Form II of sertraline hydrochloride by the removal of the solvent. In general, the Form II of sertraline hydrochloride in dry solid state may be washed. Alternatively, wet solid Form II of sertraline hydrochloride obtained from the process to prepare Form II sertraline hydrochloride may directly be washed without drying it. In general, the washing involves making a slurry of Form II sertraline hydrochloride in a dilute solution of an antioxidant in a suitable solvent. The tenn "solvent" includes any solvent or solvent mixture in which Form II sertraline hydrochloride is insoluble or very slightly soluble or sparingly soluble, including, for example methyl isobutyl ketone, N,N-dimethylacetamide, N,N- dimethylformamide, or mixtures thereof. The antioxidant may include conventional antioxidants used in the pharmaceutical industry, for example butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), hydroquinone, propyl gallate, ascorbyl palmitate, octyl gallate, dodecyl gallate, tocopherols, sodium or calcium ascorbate, tert-butylated hydroquinone, and the like. The resulting storage stable Form II of sertraline hydrochloride does not get discolored during its entire shelf life. It may be formulated into ordinary dosage forms such as, for example, tablets, capsules, pills, solutions, etc. h these cases, the medicaments can be prepared by conventional methods with conventional pharmaceutical excipients. The compositions include dosage forms suitable for oral, buccal, rectal, and parenteral (including subcutaneous, intramuscular, and ophthalmic) administration. The oral dosage forms may include solid dosage forms, like powder, tablets, capsules, suppositories, sachets, troches and lozenges as well as liquid suspensions, emulsions, pastes and elixirs. Parenteral dosage forms may include intravenous infusions, sterile solutions for intramuscular, subcutaneous or intravenous administration, dry powders to be reconstituted with sterile water for parenteral administration, and the like. The storage stable Fonn II of sertraline hydrochloride can be administered for the treatment of anxiety-related disorders, symptoms associated with premenstrual disorders and late luteal phase dysphoric disorders, in a warm-blooded animal. For the purpose of this disclosure, a warm-blooded animal is a member of the animal kingdom possessed of a homeostatic mechanism and includes mammals and birds. The present invention is further illustrated by the following examples which are provided merely to be exemplary of the invention and do not limit the scope of the invention. Certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention. Example 1 : Preparation of stable sertraline hydrochloride Form II Sertraline hydrochloride (1.0 g) was suspended in methyl isobutyl ketone (20 ml) at room temperature and the reaction mixture was heated slowly to 80°C. The reaction mixture was stirred at 80°C for about 2 hours and then cooled to room temperature. The product was filtered and dried under vacuum. The XRD pattern as per Figure 1 showed it to be a Form II of sertraline hydrochloride.
Example 2: Preparation of stable sertraline hydrochloride Form II Sertraline hydrochloride (1.0 g) was dissolved in dimethylacetamide (20 ml) at room temperature and the reaction mixture was heated slowly to 80°C. The reaction mixture was stirred at 80°C for about 2 hours and then cooled to -5°C. The product was filtered and dried under vacuum.
The XRD pattern as per Figure 1 showed it to be a Form II of sertraline hydrochloride.
Example 3: Preparation of storage stable sertraline hydrochloride Form II Sertraline hydrochloride (1.0 g) was suspended in methyl isobutyl ketone (20 ml) at room temperature and the reaction mixture was heated slowly to 80°C. The reaction mixture was stirred at 80°C for about 2 hours and then cooled to room temperature. The product was filtered and washed with a solution of butylated hydroxyanisole (0.1 g in 2 ml methyl isobutyl ketone) and then dried under vacuum.
The XRD pattern as per Figure 1 showed it to be a Form II of sertraline hydrochloride.
A measure of discoloration can be obtained by measuring UV absorbance. The UN absorbance of Example 3 (5% solution in methanol at about 380nm) was found to be 0.069 after storage for one year at 30°C and 55% humidity.

Claims

We Claim:
1. Storage stable Form II of sertraline hydrochloride, wherein after one year of storage at 30°C and 55% humidity the UV absorbance of a 5% solution of sertraline hydrochloride in methanol at about 380 nm does not exceed 0.1.
2. The storage stable Form II of sertraline hydrochloride of claim 1 , wherein the sertraline hydrochloride has the X-ray diffraction pattern of Figure 1.
3. A pharmaceutical composition comprising: a therapeutically effective amount of a storage stable Form II of sertraline hydrochloride; and one or more pharmaceutically acceptable carriers, excipients or diluents.
4. A process for the preparation of stable Form II of sertraline hydrochloride, the process comprising: obtaining a suspension of sertraline hydrochloride in a solvent comprising one or more of methyl isobutyl ketone, N,N-dimethylacetamide or N,N-dimethylformamide; heating the suspension; and recovering the stable Form II of sertraline hydrochloride by the removal of the solvent.
5. The process of claim 4, wherein removing the solvent comprises one or more of filtration, filtration under vacuum, decantation, and centrifugation.
6. The process of claim 4 further comprising cooling before removing the solvent.
7. The process of claim 4, further comprising additional drying of the product obtained
8. The process of claim 4, further comprising forming the product obtained into a finished dosage form.
9. A process for the preparation of storage stable Form II of sertraline hydrochloride, the process comprising: washing Form II of sertraline hydrochloride with a dilute solution of an antioxidant in a solvent; and recovering the storage stable Form II of sertraline hydrochloride by the removal of the solvent.
10. The process of claim 9, wherein the antioxidant comprises one or more of butylated hydroxyanisole, butylated hydroxytoluene, hydroquinone, propyl gallate, ascorbyl palmitate, octyl gallate, dodecyl gallate, tocopherols, sodium ascorbate, calcium ascorbate, and tert-butylated hydroquinone.
11. The process of claim 9, wherein the solvent comprises one or more of methyl isobutyl ketone, N,N-dimethylacetamide, and N,N-dimethylformamide.
12. The process of claim 9, wherein removing the solvent comprises one or more of filtration, filtration under vacuum, decantation, and centrifugation..
13. The process of claim 9, further comprising drying of the product obtained.
14. The process of claim 9, further comprising forming the product obtained into a finished dosage form.
15. The process of claim 9, wherein the Fonn II sertraline hydrochloride has the X-ray diffraction pattern of Figure 1.
16. A method of treating anxiety-related disorders, symptoms associated with premenstrual disorders and late luteal phase dysphoric disorder in a warm-blooded animal, the method comprising administering a pharmaceutical composition that includes a storage stable Form II of sertraline hydrochloride.
PCT/IB2005/000612 2004-03-10 2005-03-10 Processes for the preparation of stable polymorph of sertraline hydrochloride WO2005087706A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN409/DEL/2004 2004-03-10
IN409DE2004 2004-03-10

Publications (1)

Publication Number Publication Date
WO2005087706A1 true WO2005087706A1 (en) 2005-09-22

Family

ID=34962205

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/000612 WO2005087706A1 (en) 2004-03-10 2005-03-10 Processes for the preparation of stable polymorph of sertraline hydrochloride

Country Status (1)

Country Link
WO (1) WO2005087706A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495721B1 (en) * 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
WO2003093217A1 (en) * 2002-04-29 2003-11-13 Teva Pharmaceutical Industries Ltd. Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495721B1 (en) * 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
WO2003093217A1 (en) * 2002-04-29 2003-11-13 Teva Pharmaceutical Industries Ltd. Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof

Similar Documents

Publication Publication Date Title
US20080287550A1 (en) Sertraline hydrochloride form II and methods for the preparation thereof
WO2004106326A1 (en) Novel polymorphs of imatinib mesylate
WO2010083752A1 (en) High-purity febuxostat and the method for preparation
EP1476442A2 (en) Lansoprazole polymorphs and processes for preparation thereof
JP2023503833A (en) Crystalline form of tafamidis, its preparation method and its use
SK8872002A3 (en) Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
CA3057923A1 (en) A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
EP2321258A1 (en) Polymorphic form of rasagiline mesylate
CZ303728B6 (en) Purification process of iohexol
WO2013126394A1 (en) Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
FR2883285A1 (en) 7- (2- (4- (3-TRIFLUOROMETHYL-PHENYL) -1,2,3,6-TETRAHUDRO-PYRID-1-YL) ETHYL) ISOQUINOLINE BESYLATE SALT, ITS PREPARATION AND USE IN THERAPEUTICS
WO2005087706A1 (en) Processes for the preparation of stable polymorph of sertraline hydrochloride
JP2018518515A (en) Polymorphs of phenylaminopyrimidine compounds or salts thereof
CA3028014C (en) Crystal forms of a 9-aminomethyl substituted tetracycline compound and a preparation method thereof
WO2011100282A2 (en) Imatinib mesylate polymorphs
JP2025518760A (en) Crystalline forms of picolinamide fungicide compounds
CN111732586B (en) Crystal form of alkynyl-containing compound salt, preparation method and application
JP7450842B2 (en) Salts and polymorphs of phenylpyrimidone compounds and their pharmaceutical compositions and uses
JP6072908B2 (en) Deuterated ω-dimethylurea or polymorph of its salt
CZ2017732A3 (en) Solid form of tenapanor and hoe to prepare it
CA2525835C (en) Toremifene crystallization method
US20040266787A1 (en) Novel amorphous form of [2-[4-[(4-chlorophenyl)-phenyl methyl]-1-piperazinyl]ethoxy]acetic acid and process for the preparation thereof
EP2072510A1 (en) Crystalline form of azelastine
CN104045636B (en) The preparation method and use of coptisine halate
CN106397413B (en) 5-hydroxytryptamine receptor agonist and preparation method and application thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase